Article Menu
Need Help?
No Article Versions Notes Found
Cite
Li, Y.Y.R.; Mai, H.; Trudeau, M.E.; Mittmann, N.; Chiasson, K.; Chan, K.K.W.; Cheung, M.C. Reimbursement Recommendations for Cancer Drugs Supported by Phase II Evidence in Canada. Curr. Oncol. 2020, 27, 495-500. https://doi.org/10.3747/co.27.6489
Li YYR, Mai H, Trudeau ME, Mittmann N, Chiasson K, Chan KKW, Cheung MC. Reimbursement Recommendations for Cancer Drugs Supported by Phase II Evidence in Canada. Current Oncology. 2020; 27(5):495-500. https://doi.org/10.3747/co.27.6489
Chicago/Turabian StyleLi, Y.Y.R., H. Mai, M.E. Trudeau, N. Mittmann, K. Chiasson, K.K.W. Chan, and M.C. Cheung. 2020. "Reimbursement Recommendations for Cancer Drugs Supported by Phase II Evidence in Canada" Current Oncology 27, no. 5: 495-500. https://doi.org/10.3747/co.27.6489
APA StyleLi, Y. Y. R., Mai, H., Trudeau, M. E., Mittmann, N., Chiasson, K., Chan, K. K. W., & Cheung, M. C. (2020). Reimbursement Recommendations for Cancer Drugs Supported by Phase II Evidence in Canada. Current Oncology, 27(5), 495-500. https://doi.org/10.3747/co.27.6489
